Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)
6 affiliations
- 1Department of Public Health Edea Health District Littoral Region Cameroon
- 2Faculty of Medicine and Pharmaceutical Sciences University of Dschang Dschang Cameroon
- 3Regional Technical Group for Malaria Control Littoral Regional Public Health Delegation Douala Cameroon
- 4Cameroon Society of Epidemiology (Case) Yaoundé Cameroon
- 5Expanded Program on Immunization Ministry of Health Yaoundé Cameroon
- 6Faculty of Medicine and Pharmaceutical Sciences University of Douala Douala Cameroon
Abstract
Background and Aims: The RTS,S/AS01 malaria vaccine (MV) was introduced in Cameroon on 22 January 2024 in 42 of 200 health districts, including three in the Littoral Region (Edea, Japoma and Mbanga). This study describes early trends in severe malaria among children under 5 years of age in these three districts of the Littoral Region and explores their relation to district‐level MV coverage.
Methods: Retrospective ecological time‐trend study of routine DHIS 2 data, 2020–2024. Annual confirmed severe and uncomplicated malaria cases were described by district; 2024 was compared with 2023 and with the 2020–2023 mean. MV1–MV3 coverage and dropout were computed for 2024. MV3 coverage and the percentage change in severe cases (n = 3 districts) were explored with Pearson's correlation (exact p‐value and 95% confidence interval) and Spearman's rank correlation.
Results: Severe cases rose by 11.2% in 2024 (6,106 to 6,792) after declines of 4.7% in 2022% and 7.0% in 2023; the 2024 total was 10.3% above the 2020–2023 mean, and the rise was smaller than that between 2020 and 2021 (+ 35.8%). Increases were 14.4% in Edea, 11.5% in Japoma and 4.2% in Mbanga. MV3 coverage was 37.5%, 28.8% and 32.0%, respectively; 44.6% of children who received MV1 had not received MV3 (range 33.8%–59.3%). MV3 coverage was not informatively associated with the change in severe cases (Pearson r = 0.41, 95% CI − 0.92 to 0.97, p = 0.73; Spearman ρ = 0.50, exact p = 1.00); with three districts the analysis has virtually no power.
Conclusion: No change in severe malaria attributable to the vaccine was detectable in its first year, as expected given recent introduction and low, incomplete coverage. The 2024 increase lies within earlier year‐to‐year variation and cannot be attributed to, or against, the vaccine. Dropout between the first and third doses is substantial. Impact evaluation requires monthly time‐series analyses with comparison districts, population denominators and longer follow‐up.
Related
- Incidence and aetiology of diarrhoeal disease among children under five years in the post-rotavirus vaccine introduction era in Manhiça District, Mozambique.
- Impact of the COVID-19 pandemic on reported malaria incidence in children under five years of age in Cameroon: an interrupted time series analysis with regional heterogeneity (2017–2022)
- Spatial distribution of malaria and its associated factors across the districts of central Ethiopia region, 2025: a Bayesian conditional autoregressive model
- Status of Malaria Vaccine Introduction—Africa, 2019–2024
- Seasonal malaria chemoprevention introduction is associated with sustained reductions in childhood malaria burden in northern Ghana
BibTeX
@article{ndjock2026preliminary,
title = {{Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)}},
author = {Alex Stéphane Ndjip Ndjock and Michaela Josee Meli and Nina Ngouenko Nkakoua and Steve Roland Souga and Prince Théophile Djomou and Marie‐Michelle Ekedy‐Lea and Esther Laura Nyame Dipepa Nwall},
journal = {Health Science Reports},
year = {2026},
month = nov,
doi = {10.1002/hsr2.73475},
url = {https://doi.org/10.1002/hsr2.73475},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)
AU - Alex Stéphane Ndjip Ndjock
AU - Michaela Josee Meli
AU - Nina Ngouenko Nkakoua
AU - Steve Roland Souga
AU - Prince Théophile Djomou
AU - Marie‐Michelle Ekedy‐Lea
AU - Esther Laura Nyame Dipepa Nwall
PY - 2026
DA - 2026/11/04
JO - Health Science Reports
DO - 10.1002/hsr2.73475
UR - https://doi.org/10.1002/hsr2.73475
AB - Background and Aims: The RTS,S/AS01 malaria vaccine (MV) was introduced in Cameroon on 22 January 2024 in 42 of 200 health districts, including three in the Littoral Region (Edea, Japoma and Mbanga). This study describes early trends in severe malaria among children under 5 years of age in these three districts of the Littoral Region and explores their relation to district‐level MV coverage. Methods: Retrospective ecological time‐trend study of routine DHIS 2 data, 2020–2024. Annual confirmed severe and uncomplicated malaria cases were described by district; 2024 was compared with 2023 and with the 2020–2023 mean. MV1–MV3 coverage and dropout were computed for 2024. MV3 coverage and the percentage change in severe cases (n = 3 districts) were explored with Pearson's correlation (exact p‐value and 95% confidence interval) and Spearman's rank correlation. Results: Severe cases rose by 11.2% in 2024 (6,106 to 6,792) after declines of 4.7% in 2022% and 7.0% in 2023; the 2024 total was 10.3% above the 2020–2023 mean, and the rise was smaller than that between 2020 and 2021 (+ 35.8%). Increases were 14.4% in Edea, 11.5% in Japoma and 4.2% in Mbanga. MV3 coverage was 37.5%, 28.8% and 32.0%, respectively; 44.6% of children who received MV1 had not received MV3 (range 33.8%–59.3%). MV3 coverage was not informatively associated with the change in severe cases (Pearson r = 0.41, 95% CI − 0.92 to 0.97, p = 0.73; Spearman ρ = 0.50, exact p = 1.00); with three districts the analysis has virtually no power. Conclusion: No change in severe malaria attributable to the vaccine was detectable in its first year, as expected given recent introduction and low, incomplete coverage. The 2024 increase lies within earlier year‐to‐year variation and cannot be attributed to, or against, the vaccine. Dropout between the first and third doses is substantial. Impact evaluation requires monthly time‐series analyses with comparison districts, population denominators and longer follow‐up.
SN - 2398-8835
ER -